We are live on ! Find out more
BG

Bahl & Gaynor Portfolio holdings

AUM $19.8B
1-Year Est. Return 19.53%
This Fund
S&P 500
This Quarter Est. Return
+10.38%
1 Year Est. Return
+19.53%
3 Year Est. Return
+63.97%
5 Year Est. Return
+84.2%
10 Year Est. Return
+296.44%
AUM
$16.6B
AUM Growth
+$973M
Cap. Flow
-$466M
Cap. Flow %
-2.8%
Top 10 Hldgs %
30.85%
Holding
337
New
11
Increased
98
Reduced
190
Closed
11

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$43.9M
2
DELL icon
Dell
DELL
+$36.8M
3
CME icon
CME Group
CME
+$29.7M
4
AFG icon
American Financial Group
AFG
+$18.4M
5
WMB icon
Williams Companies
WMB
+$16.6M

Top Sells

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$49.2M
2
AVGO icon
Broadcom
AVGO
+$43.2M
3
UPS icon
United Parcel Service
UPS
+$26.7M
4
PLD icon
Prologis
PLD
+$26.4M
5
ABT icon
Abbott
ABT
+$26M

Sector Composition

Rank Sector Weight
1 Technology 22.48%
2 Healthcare 14.22%
3 Financials 13.06%
4 Industrials 12.03%
5 Consumer Staples 11.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MMM icon
226
3M
MMM
$94.3B
$1.43M 0.01%
15,678
-163
-1% -$13.1K
CSX icon
227
CSX Corp
CSX
$93.1B
$1.42M 0.01%
41,011
-1,063
-3% -$33.9K
IBM icon
228
IBM
IBM
$224B
$1.35M 0.01%
8,284
-573
-6% -$86.6K
VWO icon
229
Vanguard FTSE Emerging Markets ETF
VWO
$126B
$1.35M 0.01%
32,922
-9,032
-22% -$358K
CAT icon
230
Caterpillar
CAT
$387B
$1.32M 0.01%
4,472
-65
-1% -$16.9K
BF.B icon
231
Brown-Forman Class B
BF.B
$13.1B
$1.25M 0.01%
21,947
-53
-0.2% -$3.04K
EHC icon
232
Encompass Health
EHC
$12.4B
$1.24M 0.01%
18,608
+55
+0.3% +$3.56K
SHW icon
233
Sherwin-Williams
SHW
$89.8B
$1.21M 0.01%
3,886
-339
-8% -$91.2K
STZ icon
234
Constellation Brands
STZ
$23.2B
$1.18M 0.01%
4,900
+657
+15% +$156K
MCHP icon
235
Microchip Technology
MCHP
$46B
$1.17M 0.01%
12,990
-285
-2% -$23.2K
CVS icon
236
CVS Health
CVS
$122B
$1.12M 0.01%
14,153
-320
-2% -$22.8K
GILD icon
237
Gilead Sciences
GILD
$165B
$1.08M 0.01%
13,390
-1,155
-8% -$89.9K
FR icon
238
First Industrial Realty Trust
FR
$8.44B
$1.06M 0.01%
20,097
-1,028
-5% -$47.9K
WBA
239
DELISTED
Walgreens Boots Alliance
WBA
$1.06M 0.01%
40,528
-8,624
-18% -$193K
WST icon
240
West Pharmaceutical
WST
$24.9B
$1.03M 0.01%
2,926
-214
-7% -$75.7K
ZBH icon
241
Zimmer Biomet
ZBH
$18.4B
$1.02M 0.01%
8,361
-71
-0.8% -$7.92K
HMN icon
242
Horace Mann Educators
HMN
$2.11B
$992K 0.01%
30,337
-33,735
-53% -$1.08M
MCO icon
243
Moody's
MCO
$82.7B
$987K 0.01%
2,527
-10
-0.4% -$3.48K
TSM icon
244
TSMC
TSM
$2.18T
$970K 0.01%
9,330
+2,000
+27% +$191K
FTV icon
245
Fortive
FTV
$18.6B
$944K 0.01%
17,012
+7,148
+72% +$377K
MLAB icon
246
Mesa Laboratories
MLAB
$574M
$942K 0.01%
8,988
-47
-0.5% -$4.58K
POOL icon
247
Pool Corp
POOL
$7.5B
$934K 0.01%
2,342
-612
-21% -$215K
STAG icon
248
STAG Industrial
STAG
$7.19B
$924K 0.01%
23,525
-1,610
-6% -$57.1K
HI
249
DELISTED
Hillenbrand
HI
$917K 0.01%
19,160
-300
-2% -$12.3K
DE icon
250
Deere & Co
DE
$168B
$912K 0.01%
2,281
-90
-4% -$33.9K

Similar funds

Bahl & Gaynor's Q4 2023 Portfolio in Review

As of Q4 2023, Bahl & Gaynor held 337 positions worth $16.6B, up 6.2% from $15.7B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Bahl & Gaynor's Q4 2023 filing shows 11 new, 98 increased, 190 reduced and 11 closed positions. Its largest new stake was Dell: 520,900 shares worth $39.8M. The largest sale was Medtronic, an estimated $49.2M.

By sector, the portfolio is most concentrated in Technology at 22% of assets, up from 21% a quarter earlier, followed by Healthcare and Financials.

  • Bahl & Gaynor's largest Q4 2023 buy was Dell: 520,900 shares worth $39.8M.
  • Bahl & Gaynor added most to Amgen in Q4 2023, an estimated $43.9M increase.
  • Bahl & Gaynor's biggest Q4 2023 reduction was Medtronic, cutting an estimated $49.2M.
  • Bahl & Gaynor fully exited SBA Communications in Q4 2023, selling an estimated $375K.
  • Bahl & Gaynor's ten largest holdings make up 31% of its $16.6B portfolio in Q4 2023.
  • Bahl & Gaynor opened 11 new positions and closed 11 in Q4 2023.
  • Bahl & Gaynor's portfolio value rose 6.2% quarter-over-quarter to $16.6B.

Based on Bahl & Gaynor's 13F filing for Q4 2023, filed 2 Feb 2024.